During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every...
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...
WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- As the medication experts, APhA affirms there has been no new evidence in two...
Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system...
Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for...
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and...
PHILADELPHIA, PA / ACCESS Newswire / September 16, 2025 / TruMerit, a global leader in healthcare workforce development, today launched...
MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA...
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...
Richmond Hill, Ontario--(Newsfile Corp. - September 16, 2025) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian leader...
"Trump's Deregulatory Mandate Is Finally Driving DEA Marijuana Policy Reform," states Duane Boise, CEO of MMJ BioPharma Cultivation.Under President Trump's...
Adopted across Fortune 500 employers, benefits partners, and insurers, Goodpath delivers integrative care for weight, MSK pain, sleep, diabetes, digestive health,...
Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month...
The study represents the first successful prospective genetic biomarker-guided drug trial in psychiatrySAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) --...
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101...
Close to $600,000 in Funding Provided to 14 Academic Researchers from Across the US to Advance New Innovations to Predict,...
Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...